[go: up one dir, main page]

WO2007136990A3 - Prolyl hydroxylase inhibitors - Google Patents

Prolyl hydroxylase inhibitors Download PDF

Info

Publication number
WO2007136990A3
WO2007136990A3 PCT/US2007/068419 US2007068419W WO2007136990A3 WO 2007136990 A3 WO2007136990 A3 WO 2007136990A3 US 2007068419 W US2007068419 W US 2007068419W WO 2007136990 A3 WO2007136990 A3 WO 2007136990A3
Authority
WO
WIPO (PCT)
Prior art keywords
prolyl hydroxylase
hydroxylase inhibitors
anemia
antagonists
inhibition
Prior art date
Application number
PCT/US2007/068419
Other languages
French (fr)
Other versions
WO2007136990A2 (en
Inventor
Duke M Fitch
Deping Chai
Original Assignee
Smithkline Beecham Corp
Duke M Fitch
Deping Chai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Duke M Fitch, Deping Chai filed Critical Smithkline Beecham Corp
Priority to JP2009511156A priority Critical patent/JP2009537558A/en
Priority to US12/299,835 priority patent/US20090176825A1/en
Publication of WO2007136990A2 publication Critical patent/WO2007136990A2/en
Publication of WO2007136990A3 publication Critical patent/WO2007136990A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I ) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
PCT/US2007/068419 2006-05-16 2007-05-08 Prolyl hydroxylase inhibitors WO2007136990A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009511156A JP2009537558A (en) 2006-05-16 2007-05-08 Prolyl hydroxylase inhibitor
US12/299,835 US20090176825A1 (en) 2006-05-16 2007-05-08 Prolyl hydroxylase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74731206P 2006-05-16 2006-05-16
US60/747,312 2006-05-16

Publications (2)

Publication Number Publication Date
WO2007136990A2 WO2007136990A2 (en) 2007-11-29
WO2007136990A3 true WO2007136990A3 (en) 2008-04-24

Family

ID=38723955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/068419 WO2007136990A2 (en) 2006-05-16 2007-05-08 Prolyl hydroxylase inhibitors

Country Status (3)

Country Link
US (1) US20090176825A1 (en)
JP (1) JP2009537558A (en)
WO (1) WO2007136990A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445680B2 (en) 2008-02-25 2013-05-21 Merck Sharp & Dohme Corp. Tetrahydrothieno pyridines

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PT2044005E (en) 2006-06-26 2010-12-17 Warner Chilcott Co Llc Prolyl hydroxylase inhibitors and methods of use
EP2097416B1 (en) 2006-12-18 2012-09-12 Amgen, Inc Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2111399A2 (en) 2006-12-18 2009-10-28 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
ES2446418T3 (en) 2007-04-18 2014-03-07 Amgen, Inc Indanone derivatives that inhibit prolyl hydroxylase
ES2442847T3 (en) 2007-04-18 2014-02-13 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
CN101663037A (en) * 2007-04-18 2010-03-03 默克公司 Novel 1,8-naphthyridine compounds
US8097620B2 (en) 2007-05-04 2012-01-17 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
ES2389063T3 (en) 2007-05-04 2012-10-22 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
JP2011513221A (en) * 2008-02-25 2011-04-28 メルク・シャープ・エンド・ドーム・コーポレイション Tetrahydroflopyridone
CN101951776A (en) * 2008-02-25 2011-01-19 默沙东公司 Tetrahydro-1H-pyrrolo fused pyridones
EP2257539B1 (en) * 2008-03-18 2014-09-10 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
WO2009134754A1 (en) 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazole glycinamides as prolyl hydroxylase inhibitors
GB0809262D0 (en) 2008-05-21 2008-06-25 Isis Innovation Assay
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
WO2010022308A1 (en) * 2008-08-21 2010-02-25 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP5649584B2 (en) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Thiochromene derivatives as HIF hydroxylase inhibitors
WO2010059555A1 (en) * 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
KR101787116B1 (en) 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 Bicyclic pyrazolo-heterocycles
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
ES2477968T3 (en) 2009-07-17 2014-07-18 Japan Tobacco, Inc. Triazolopyridine compound, and its action as a prolyl hydroxylase inhibitor and inducer of erythropoietin production
JP5718236B2 (en) 2009-10-21 2015-05-13 第一三共株式会社 5-hydroxypyrimidine-4-carboxamide derivatives
SI2496084T1 (en) 2009-11-06 2015-08-31 Aerpio Therapeutics Inc. Compositions and methods for treating colitis
CN103608346B (en) 2011-02-02 2016-06-15 菲布罗根有限公司 As the 7-naphthyridine derivatives of hypoxia inducible factor (HIF) hydroxylase inhibitors
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
US8865748B2 (en) 2011-06-06 2014-10-21 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (en) 2011-06-06 2018-03-17
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
JP6122862B2 (en) 2011-10-25 2017-04-26 ヤンセン ファーマシューティカ エヌ．ベー． Meglumine salt formulation of 1- (5,6-dichloro-1H-benzo [D] imidazol-2-yl) -1H-pyrazole-4-carboxylic acid
UA117122C2 (en) * 2012-12-24 2018-06-25 Каділа Хелткере Лімітед Novel quinolone derivatives
CN103059040A (en) * 2013-01-07 2013-04-24 盛世泰科生物医药技术(苏州)有限公司 Synthesizing method of 5-chloro-7-methoxy thieno[3,2-b]pyridine
SMT202400092T1 (en) 2013-06-13 2024-05-14 Akebia Therapeutics Inc Compositions and methods for treating anemia
EP3068394A4 (en) 2013-11-15 2017-04-26 Akebia Therapeutics Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
AU2015311333B2 (en) 2014-09-02 2017-11-16 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
WO2016045125A1 (en) 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
JP2018039733A (en) * 2014-12-22 2018-03-15 株式会社富士薬品 Novel heterocyclic derivative
EP3247355A4 (en) 2015-01-23 2018-06-13 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CU20170126A7 (en) 2015-04-01 2018-07-05 Akebia Therapeutics Inc COMPOSITIONS AND METHODS TO TREAT ANEMIA
SG11201802777XA (en) 2015-10-14 2018-05-30 X Therma Inc Compositions and methods for reducing ice crystal formation
CN108069957B (en) * 2016-11-09 2022-11-04 广东东阳光药业有限公司 Prolyl hydroxylase inhibitors and uses thereof
CN107739378A (en) * 2017-11-14 2018-02-27 杭州安道药业有限公司 Indole derivative and its application in medicine
CN107759564B (en) * 2017-11-28 2020-05-22 中国药科大学 Triazole picolinyl glycine compound, its method and medical use
WO2019217550A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437132B2 (en) * 1997-08-13 2002-08-20 Takeda Chemical Industries, Ltd. Thienopyridine derivatives, their intermediates and production thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437132B2 (en) * 1997-08-13 2002-08-20 Takeda Chemical Industries, Ltd. Thienopyridine derivatives, their intermediates and production thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445680B2 (en) 2008-02-25 2013-05-21 Merck Sharp & Dohme Corp. Tetrahydrothieno pyridines

Also Published As

Publication number Publication date
WO2007136990A2 (en) 2007-11-29
JP2009537558A (en) 2009-10-29
US20090176825A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
WO2007103905A3 (en) Prolyl hydroxylase inhibitors
WO2007136990A3 (en) Prolyl hydroxylase inhibitors
WO2008089052A3 (en) N-substituted glycine derivatives: hydroxylase inhibitors
WO2007150011A3 (en) Prolyl hydroxylase inhibitors
WO2010022307A3 (en) Prolyl hydroxylase inhibitors
WO2009073497A3 (en) Prolyl hydroxylase inhibitors
EA201000920A1 (en) PROHYL HYDROXYLASE INHIBITORS
EA201100688A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2008013838A3 (en) Pyridizinone derivatives
EA200970557A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
HRP20130797T1 (en) Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase
WO2008005877A3 (en) Inhibitors of c-kit and uses thereof
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007079164A3 (en) Protein kinase inhibitors
ATE451363T1 (en) 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2007079199A3 (en) Substituted bis-amide metalloprotease inhibitors
WO2007057768A3 (en) Sulfonyl derivatives
WO2006050109A3 (en) Novel kinase inhibitors
WO2008137084A3 (en) Diazaquinolones that inhibit prolyl hydroxylase activity
WO2008076427A3 (en) Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
WO2007016674A3 (en) 2-aminoaryl pyridines as protein kinases inhibitors
WO2008061108A3 (en) Phthalazine derivatives
WO2006117761A3 (en) Magnesium salts of hmg-coa reductase inhibitors
WO2009137291A3 (en) Spiroazaindoles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07761981

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12299835

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2009511156

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07761981

Country of ref document: EP

Kind code of ref document: A2